NextCure, Inc.
NXTC · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.06 | -1.07 | 0.03 |
| FCF Yield | -173.27% | -96.66% | -32.12% | -30.33% |
| EV / EBITDA | -0.47 | 0.23 | 0.02 | -1.36 |
| Quality | ||||
| ROIC | -72.69% | -18.65% | -17.09% | -15.25% |
| Gross Margin | 0.00% | 0.00% | 50.00% | 0.00% |
| Cash Conversion Ratio | 0.73 | 0.85 | 1.18 | 0.60 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -74.80% | -87.37% | 40.34% | -15.35% |
| Safety | ||||
| Net Debt / EBITDA | 0.01 | 1.46 | 1.85 | 1.89 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -361.71 | -376.51 | 8.23 | -464.53 |